Taipei Medical University Institutional Repository:Item 987654321/57941
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 45422/58598 (78%)
造访人次 : 2549859      在线人数 : 176
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://libir.tmu.edu.tw/handle/987654321/57941


    题名: 探討卵巢癌早期病患對於Platinum合併Cyclophosphamide與Platinum合併Paclitaxel兩種處方之療效比較分析
    Comparative Effectiveness of Platinum plus Paclitaxel versus Platinum plus Cyclophosphamide in Patients with Early-staged Ovarian Cancer
    作者: 陳建安
    Chen, Chien-An
    贡献者: 醫務管理學研究所
    湯澡薰
    关键词: 早期卵巢癌;Cyclophosphamide;Paclitaxel;無病存活率;整體存活率;臺灣全民健保資料庫
    early-staged ovarian cancer;Cyclophosphamide;Paclitaxel;disease-free survival;overall survival;National Health Insurance, Taiwan
    日期: 2014-06-18
    上传时间: 2019-09-03 10:23:01 (UTC+8)
    摘要: 卵巢癌的治療方式為分期手術加上輔助性化療，大多數的臨床試驗研究都以晚期的卵巢癌患者為研究對象，對於早期的卵巢癌患者的研究較少，對於早期的患者而言，使用Platinum合併Cyclophosphamide化療處方與Platinum合併Paclitaxel化療處方的療效比較尚未定論，而在臺灣健保只給付Platinum合併Cyclophosphamide化療處方，對於使用Platinum合併Paclitaxel化療處方的患者則需要自費使用Paclitaxel。因此本研究的研究目的主要是比較早期卵巢癌患者接受Platinum 合併 Cyclophosphamide化療處方或Platinum合併Paclitaxel化療處方之無病存活率與整體存活率，並以45歲(停經開始)作為年齡分層，以及療程次數的分層研究。
    本研究利用全民健保資料庫中的癌症特殊需求檔為資料來源，針對Platinum 合併 Cyclophosphamide治療處方與Platinum合併Paclitaxel治療處方以Kaplan-Meier計算存活率，並以Cox Proportional Hazard Model計算不同化療處方的危險性。
    研究結果顯示，在638位納入研究的對象當中，其中使用Platinum 合併 Cyclophosphamide化療處方有376人，5年無病存活率為0.78，5年整體存活率為0.84；使用Platinum合併Paclitaxel化療處方有262人，5年無病存活率為0.82，5年整體存活率為0.86。在不同用藥處方的無病存活分析中，以Platinum 合併 Cyclophosphamide化療處方為比較組，Platinum合併Paclitaxel化療處方2年復發的危險性為0.57(95%信賴區間為0.33-0.97)，5年復發的危險性為0.73(95%信賴區間為0.46-1.14)，2年死亡的危險性為0.56(95%信賴區間為0.25-1.28)，5年死亡的危險性為0.73(95%信賴區間為0.41-1.27)。在合併不同療程次數的年齡分層分析中，針對45歲以上病患做為研究對象時，以使用Platinum 合併 Cyclophosphamide化療處方3次至5次療程為比較組，Platinum 合併 Cyclophosphamide化療處方6次療程的2年復發危險性為0.43(95%信賴區間為0.21-0.88)，使用Platinum合併Paclitaxel化療處方3次至5次療程的2年復發危險性為0.20(95%信賴區間為0.08-0.71)，使用Platinum合併Paclitaxel化療處方6次療程的2年復發危險性為0.18(95%信賴區間為0.09-0.56)；Platinum 合併 Cyclophosphamide化療處方6次療程的5年復發危險性為0.63(95%信賴區間為0.35-1.16)，使用Platinum合併Paclitaxel化療處方3次至5次療程的5年復發危險性為0.43(95%信賴區間為0.18-1.05)，使用Platinum合併Paclitaxel化療處方6次療程的5年復發危險性為0.36(95%信賴區間為0.19-0.89)。針對45歲以下的患者使用Platinum合併Paclitaxel化療處方與使用Platinum 合併 Cyclophosphamide化療處方於復發及死亡的危險性並未達顯著差異，
    根據本研究的結果，建議，45歲以上的早期卵巢癌患者應使用Platinum合併Paclitaxel化療處方6次療程，以減少復發的危險性。
    The use of postoperative chemotherapy is standard for many patients with early-stage ovarian cancer. Previous studies have showed a survival advantage for patients treated with combinations of platinum and paclitaxel, as compared with those given a platinum plus cyclophosphamide in the first line therapy among patients with advanced ovarian cancer. However, little has been known if the incorporation of paclitaxel into first-line therapy improves the health outcomes in women with early stage ovarian cancer. This study aims to fill this knowledge gap.
    The data source for this study is 2000-2011 National Health Insurance Research Database (NHIRD). The including and excluding criteria for the study subjects are (1) patients who were first diagnosed as ovarian cancer during 2001-2010 and had never had any other types of cancer during 2000-2011; (2) patients who received surgeries related to early-stage ovarian cancer; (3) patients who received platinum plus cyclophosphamide treatment (the PC group) or platinum plus paclitaxel treatment regimen (the PT group) within 60 days after the surgery; and (4) patients who received at least 3 cycles of the treatment and had never switched between the two regimens. There were 638 subjects identified, of which 376 patients were in the PT group and 262 patients in the PC group. The Kaplan-Meier method and the Cox proportional hazard model were used to estimate the duration of disease-free survival (DFS) and of overall survival (OS) between PC and PT.
    When compared with PC, the hazard ratios of the 2-year DFS and OS for PT was 0.57 (95% CIs: 0.33-0.97) and 0.56 (95% CIs: 0.25-1.28), respectively. The hazard ratios of the 5-year DFS and the OS for PT was 0.73 (95% CIs : 0.46-1.14) and 0.73 (95%CIs : 0.41-1.27), respectively. The subgroup analysis showed that, for women aged 45 years and above, when compared with women who completed 3-5 cycles of PC, the 2-year hazard ratio of DFS for women with of 6 cycles of PC ws 0.43 (95% CIs: 0.21-0.88), for women with 3-5 cycles of PT was 0.20 (95% CIs: 0.08-0.71), and for women with 6 cycles of PT was 0.18 (95% CIs: 0.09-0.56). The 5-year hazard ratio of DFS for women with 6 cycles of PC was 0.63 (95% CIs: 0.35-1.16), for women with 3-5 cycles of PT was 0.43 (95% CIs: 0.18-1.05), and for women with 6 cycles of PT was 0.36 (95% CIs: 0.19-0.89).
    It seems that the most effective treatment strategy for women > 45 years old with early ovarian cancer is the PT treatment for 6 cycles. For women <= 45 years old, however, PT was not found to significantly improve the treatment outcomes in terms of DFS and OS.
    描述: 碩士
    指導教授-湯澡薰
    委員-鄭文芳
    委員-黃國哲
    数据类型: thesis
    显示于类别:[醫務管理學系暨研究所] 碩博士論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    index.html0KbHTML222检视/开启


    检视Licence

    在TMUIR中所有的数据项都受到原著作权保护.

    TAIR相关文章

    著作權聲明 Copyright Notice

    • 本平台之數位內容為臺北醫學大學所收錄之機構典藏，包含體系內各式學術著作及學術產出。秉持開放取用的精神，提供使用者進行資料檢索、下載與取用，惟仍請適度、合理地於合法範圍內使用本平台之內容，以尊重著作權人之權益。商業上之利用，請先取得著作權人之授權。

      The digital content on this platform is part of the Taipei Medical University Institutional Repository, featuring various academic works and outputs from the institution. It offers free access to academic research and public education for non-commercial use. Please use the content appropriately and within legal boundaries to respect copyright owners' rights. For commercial use, please obtain prior authorization from the copyright owner.

    • 瀏覽或使用本平台，視同使用者已完全接受並瞭解聲明中所有規範、中華民國相關法規、一切國際網路規定及使用慣例，並不得為任何不法目的使用TMUIR。

      By utilising the platform, users are deemed to have fully accepted and understood all the regulations set out in the statement, relevant laws of the Republic of China, all international internet regulations, and usage conventions. Furthermore, users must not use TMUIR for any illegal purposes.

    • 本平台盡力防止侵害著作權人之權益。若發現本平台之數位內容有侵害著作權人權益情事者，煩請權利人通知本平台維護人員([email protected])，將立即採取移除該數位著作等補救措施。

      TMUIR is made to protect the interests of copyright owners. If you believe that any material on the website infringes copyright, please contact our staff([email protected]). We will remove the work from the repository.

    Back to Top
    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈